Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Trial Profile

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Neratinib (Primary)
  • Indications Advanced breast cancer; Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Nov 2016 According to a Puma Biotechnology media release, trial design of this trial will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
    • 28 Oct 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top